Lasofoxifene in postmenopausal women with osteoporosis - Wikidata - wikimedia - TriplyDB

Lasofoxifene in postmenopausal women with osteoporosis

Lasofoxifene in postmenopausal women with osteoporosis

http://www.wikidata.org/entity/Q28274186

about

GPER Function in Breast Cancer: An Overview Surgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature review Molecular cancer prevention: Current status and future directions The evolution of selective estrogen receptor modulators in osteoporosis therapy The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice An overview on the treatment of postmenopausal osteoporosis Exemestane for breast cancer prevention: a critical shift?Influence of exercise on bone remodeling-related hormones and cytokines in ovariectomized rats: a model of postmenopausal osteoporosis Medical prevention of breast cancer The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.Current strategies for the prevention of breast cancer GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure.New selective estrogen receptor modulators (SERMs) in development Update on estrogens and the skeleton Selective estrogen receptor modulators: tissue specificity and clinical utility.Prevalence and risk factors of vertebral compression fractures in female SLE patients.Emerging therapeutic opportunities for skeletal restoration.Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Prevention and treatment of postmenopausal osteoporosis.From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators Estrogen receptor ligands: a patent review update.Preventative therapies for healthy women at high risk of breast cancer.Estrogens and Androgens in Skeletal Physiology and Pathophysiology.Treatment of osteopenia.Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.Gender differences in osteoporosis and fractures Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780.The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function.Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis.Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications The naphthol selective estrogen receptor modulator (SERM), LY2066948, is oxidized to an o-quinone analogous to the naphthol equine estrogen, equilenin.Tissue-Specific Effects of Loss of Estrogen during Menopause and Aging.Is there a future for selective estrogen-receptor modulators in osteoporosis?Medical treatment of osteoporotic vertebral fractures.

P2860

Q21131274-1F37C1FA-C403-4539-AC1A-71456FF44242 Q26744057-65BCCF34-79AD-4560-8F6D-B165024F8542 Q26797207-F8D41EAA-AF4F-4CD3-8D43-4E4E1280658E Q26827973-18F3F80E-7DBD-4292-90FA-A503574CA4CB Q26830744-6BD6EF54-CA1C-475E-96D9-646B218C49C5 Q27013070-EDD0BFF7-742C-4CB9-9192-1AF731B90FF3 Q27028211-706FBB67-72D9-4D9A-8F1D-7B0B189A7F70 Q27325588-C8B24CC5-1BC7-43FE-BEA0-E337829A04D9 Q28086915-A0D79F7F-B03A-4F0A-9266-54DE8EA72759 Q28539057-0A5794DD-248F-4D28-BBEC-D3E771A8B475 Q30413295-DB82C93F-2CAF-4E5C-9CF4-CE6F152B099E Q30456770-1D1A04CA-0CE1-4D3F-8E3B-DCD1AFC6799C Q30620889-5AF119BB-998D-40CB-A70D-F16B019D001C Q33599463-1815ED31-ADBC-4E2C-A85F-89D5D70791F6 Q33835934-3995C132-64ED-444C-B797-6D7276FF41CA Q33988035-6F7357D2-EA40-496B-9F41-E4447CC80AC3 Q34031994-58D5D2A4-068C-43A5-B1EE-29510594F6F8 Q34134828-D1F4740D-B7D4-475C-B522-30CFA0189FEA Q34153085-6E468437-343C-43D5-971E-9E206C45948B Q34161867-FB19069C-847D-40ED-B07E-25EE9EE9FA6A Q34189582-E648B56D-22DC-468F-BFD4-6ABD844B9A69 Q34296614-5007C98E-1041-474D-A549-49714DA56431 Q34315413-19B8F7F6-8579-411C-9499-A1DD8B1FCED0 Q34315816-22187D9A-5B35-49EA-9F00-2BA21FC6B116 Q34347152-B3990B6F-F5C7-4BA6-BDE9-68AFF35EDCB5 Q34393592-455048AB-EDD8-4AD9-BC50-7D18D21FE13C Q34543980-DF89B763-A252-4D33-906D-D3EA09F49057 Q34630644-132B3207-5049-48DE-BD52-C17088D0D59B Q34896573-5B849527-6561-4572-B35D-F3EE214C6943 Q35023715-9C658527-3AEF-4C6D-9747-21E327D27BFD Q35036417-00848957-1A07-42F6-ACB2-91BFA39FAD4B Q35092609-31BC97EB-F5B1-4808-A720-F12BE83E0B68 Q35447240-28A38436-4F6D-4DDC-8692-9D469465C7B5 Q35551803-B043C027-6F07-41CD-A143-7F51610C80DF Q35557927-C3D89933-FF7B-4205-9242-33625F362CF3 Q35740351-F2D3A016-10EF-4ED4-81C2-1D3484D6EFBB Q35869879-2CE3E958-63F3-472E-BB42-60702C4B3BFB Q35971744-81B2B061-2733-4B78-A75C-772A2F582189 Q36059531-736DFC48-EBF4-4BEA-BE92-D0017AD57044 Q36059589-D6049CB6-E1D3-4632-9DB5-AEBAF04D189D

P2860

Lasofoxifene in postmenopausal women with osteoporosis

http://www.wikidata.org/entity/Q28274186

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Lasofoxifene in postmenopausal women with osteoporosis

@ast

Lasofoxifene in postmenopausal women with osteoporosis

@en

Lasofoxifene in postmenopausal women with osteoporosis

@nl

type

label

Lasofoxifene in postmenopausal women with osteoporosis

@ast

Lasofoxifene in postmenopausal women with osteoporosis

@en

Lasofoxifene in postmenopausal women with osteoporosis

@nl

prefLabel

Lasofoxifene in postmenopausal women with osteoporosis

@ast

Lasofoxifene in postmenopausal women with osteoporosis

@en

Lasofoxifene in postmenopausal women with osteoporosis

@nl

P1433

Q28274186-99C491AB-0957-4E98-9F3F-6E051BA581FD

P1476

Q28274186-E3E73D52-2A5E-4106-A7F9-2C20516229DE

P2093

Q28274186-1068F3C3-3153-4A92-802D-3C463F3BDF45

Q28274186-31BC6643-BB9B-4185-9478-DB94A5D99E48

Q28274186-3A9DE821-9AA0-4BF5-A970-EACF3B246677

Q28274186-3DC78879-30CB-41BD-8578-7603A0186046

Q28274186-4E5E47E3-8045-4B6B-AB28-76300B6FB5FF

Q28274186-726ED6AE-3551-483E-A313-58559C17EABA

Q28274186-84B59EE5-1C1A-497B-8E4F-06002F7ABBC1

Q28274186-87ACEB4D-BA03-4E1D-9D8B-CAB9CAC5805C

Q28274186-99D68C48-DA89-4656-8FDE-3A8FE28BBEA2

Q28274186-9A75FE67-F37F-4DE1-AF23-46F28E19F5F8

P304

Q28274186-D97D6E7C-14BE-4D11-92BC-BBEDFCBABC02

P31

Q28274186-57091406-6525-4A1B-883C-2B96F5C27B39

P3181

Q28274186-84C0E59E-6F0F-4CB0-97F9-458ED6E685D3

P356

Q28274186-8BA68854-26D6-498B-A470-63294F2951E5

P407

Q28274186-B858C6CA-62FF-4AC1-A20E-F0C137A58933

P433

Q28274186-024FD689-DF3D-41A6-9CC8-2A99DA624F72

P478

Q28274186-5C42158B-8C36-4777-87DE-F37027AE1CE4

P50

Q28274186-59BD7479-18B9-489E-9B33-BEAFF0D750D5

P577

Q28274186-5DD43749-A337-4C9D-80E3-84A1E4F50827

P698

Q28274186-E5C436DE-25C6-47A2-B071-A8C384395152

P921

Q28274186-858A33D0-2E36-4239-86F7-8EEB10BA3AF3

P3181

P356

P1433

The New England Journal of Medicine

P1476

Lasofoxifene in postmenopausal women with osteoporosis

@en

P2093

Andrea Z LaCroix

http://www.w3.org/2001/XMLSchema#string

Andy Lee

http://www.w3.org/2001/XMLSchema#string

David D Thompson

http://www.w3.org/2001/XMLSchema#string

David M Reid

http://www.w3.org/2001/XMLSchema#string

John Thompson

http://www.w3.org/2001/XMLSchema#string

Jose Zanchetta

http://www.w3.org/2001/XMLSchema#string

Kristine Ensrud

http://www.w3.org/2001/XMLSchema#string

Patrick Neven

http://www.w3.org/2001/XMLSchema#string

Pierre D Delmas

http://www.w3.org/2001/XMLSchema#string

Richard Eastell

http://www.w3.org/2001/XMLSchema#string

P304

686-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2477652

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0808692

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20181970

http://www.w3.org/2001/XMLSchema#string

P921